Alvarez Ralph 4

What Happened Ralph Alvarez, a director of Eli Lilly & Co. (LLY), was credited with 11.985 stock units on 2026-02-17 as a grant/award (transaction code A). The units are valued at $1,036.05 each, for a total reported value of approximately $12,417. This was an award/deferred compensation transaction, not an open‑market purchase or sale.

Key Details

• Transaction date and filing: Acquired 11.985 units on 2026-02-17; Form 4 filed 2026-02-18 (timely).
• Price/value: $1,036.05 per share equivalent; total ≈ $12,417.
• Shares owned after transaction: Not reported in this filing.
• Footnotes: (1) Alvarez elected to defer these shares in lieu of cash under the Lilly Directors' Deferral Plan; the units will be settled in shares following his separation from service. (2) Reporting person disclaims beneficial ownership except for his pecuniary interest.
• Transaction code: A (grant/award/other acquisition).

Context This is a routine director compensation deferral — common practice to receive board pay as deferred stock units. Because the units are deferred and will be settled only after separation, this filing does not reflect an immediate purchase or sale that signals near‑term market action by the director. The reporting person’s disclaimer indicates limited beneficial ownership beyond economic interest in the deferred units.